INC Research is a leading global CRO providing Phase I to IV clinical development services across six continents. Our global scale and scope, broad therapeutic expertise and commitment to operational excellence using our proven Trusted Process® allow us to develop innovative and flexible strategic alliances. By sharing incentives, ensuring dedicated resources, standardizing processes and customizing reporting, these alliances encourage long-term, multi-drug partnerships that save time and money while producing actionable data that enables efficient product potential assessments and frees our customers to think about the next big thing. In fact, such alliances have helped us contribute to the development of 19 of the top 20 selling medicines on the market today, improving quality of life for patients worldwide.
Global reach, local presence
The complexity of today’s large global trials means you need a CRO with the critical mass to deliver any study, anywhere. With experience spanning more than 100 countries, our vast global network enables us to do just that. As well as providing access to international patient populations, this network also ensures ideas and innovations are shared across continents, demographic patterns are matched and the benefits of emerging markets are leveraged.
Broad therapeutic expertise
We pride ourselves on our long-standing therapeutic heritage. Our extensive expertise covers more than 90 percent of drugs in development today, including those for central nervous system (CNS), oncology, cardiovascular, endocrine, infectious diseases and respiratory conditions/diseases. In fact, we believe such expertise is so important that we’ve structured our entire organization around it, dedicating highly experienced business leaders as therapeutic heads to guide your strategies.
Since 2006 INC Research has conducted all trials using our Trusted Process® – a methodology that reduces variability and increases trial outcome predictability by standardizing operational and quality controls at every stage. This allows us to deliver studies on time and on budget, without compromised data quality. Trials completed using this process report:
• Study start-up times three weeks faster than the industry average
• Patient enrollment duration on average three weeks less than originally planned
• A 35% improvement in database lock times
INC Research is not fazed by the four phases a new drug has to go through to get from idea stage to commericial adoption. The contract research organization (CRO) specializes in conducting Phase I through Phase IV clinical trials on drugs addressing a range of disorders. Its services include scientific and medical consulting, study monitoring, project management, data management, and regulatory support services. It also has divisions devoted to pediatrics and women's health trials and operates in 40 countries around the globe. The company is owned by a consortium of private equity investors.
3201 Beechleaf Court, Suite 600
Raleigh, NC 27604-1547